| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00066807 2005-002626-59 Details | 2016-10-28 Interventional | 3 | 29 | Epirubicin Exemestane Tamoxifen Triptorelin Pam… Breast Neoplasm… Breast Cancer | Poor accrual, patients were followed until completion of 5 yrs treatment Trial terminated early due to poor accrual. Adverse event data is available ONLY for selected Grade 3-5 AEs for chemotherapy arm. 25 of 29 patients were co-enrolled in TEXT (IBCSG 25-02), which reports AEs and outcomes of endocrine therapy. | |||
| NCT01231347 Details | 2016-10-27 Interventional | 3 | 800 | Antibodies, Mon… Gemcitabine Adenocarcinoma Endocrine Gland… Neoplasm Metast… Neoplasms Pancreatic Neop… Adenocarcinoma … Advanced Malign… Advanced Solid … Bone Metastases Cancer Cancer of Pancr… Cancer of the P… Endocrine Cance… Metastases Metastatic Canc… Metastatic Panc… Oncology Oncology Patien… Pancreas Cancer Pancreatic Canc… Solid Tumors | Planned independent DMC Interim review: ended for futility w/no safety concerns - | |||
| NCT01479179 Details | 2016-10-26 Interventional | 1/2 | 0 | Trastuzumab Breast Neoplasm… Breast Cancer | Drug sponsor decision to discontinue study. - | |||
| NCT01243970 Details | 2016-10-26 Interventional | 4 | 29 | Ephedrine Oxymetazoline Phenylephrine Pregnancy Spinal Anesthes… | Change in clinical practice since the start of the trial in 2011 (phenylephrine superior) - | |||
| NCT01015443 Details | 2016-10-26 Interventional | 3 | 285 | Cyclophosphamid… Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | The study is terminated prematurely as the sponsor decided to discontinue program with
Tecemotide in NSCLC. The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC. | |||
| NCT02083679 2013-003995-11 Details | 2016-10-25 Interventional | 1 | 15 | Albumin-Bound P… Antibodies, Mon… Carboplatin Cisplatin Gemcitabine Paclitaxel Pemetrexed Carcinoma, Non-… | Sponsor the return rights of the compound to the collaboration partner for further clinical
development The trial was prematurely discontinued and Expansion Cohort (Part 2) was not conducted as Sponsor decided to prematurely discontinue the development of Sym004. This decision was not related to any safety or efficacy findings regarding Sym004. | |||
| NCT00177970 Details | 2016-10-25 Interventional | 4 | 14 | Antibodies Immunoglobulin … Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Diarrhea Clostridium Dif… | We were unable to receive IVIG free from phamaceutical company. - | |||
| NCT00098371 Details | 2016-10-24 Interventional | 2 | [3 Refs] | 64 | Alvocidib Leukemia Leukemia, Lymph… Leukemia, Lymph… Leukemia, Proly… B-cell Chronic … Prolymphocytic … Refractory Chro… | CTEP Initiated Action. - | ||
| NCT02667223 2015-003568-36 Details | 2016-10-21 Interventional | 1 | 60 | Bococizumab Hypercholestero… Healthy | The study was terminated early on July 8, 2016 due to business priorities regarding study
execution. - | |||
| NCT02558361 Details | 2016-10-21 Interventional | 4 | 0 | Apremilast Arthritis Arthritis, Psor… Psoriatic Arthr… | FDA approved synovial biopsy device unavailable - | |||
| NCT01737593 Details | 2016-10-21 Interventional | 4 | 108 | Acetaminophen Emergence Delir… Psychomotor Agi… Emergence Agita… Pain | Interim analysis revealed a negative effect. - | |||
| NCT01016717 Details | 2016-10-21 Interventional | 4 | 0 | Omeprazole Pantoprazole Coronary Artery… | Since the published data resolved the study goals we decided not to start it - | |||
| NCT00023244 Details | 2016-10-21 Interventional | 2 | [2 Refs] | 274 | Basiliximab Cyclosporine Cyclosporins Methylprednisol… Prednisone Sirolimus Sulfamethoxazol… Tacrolimus Trimethoprim Trimethoprim, S… Kidney Failure,… End-Stage Renal… | Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferative
disorder - | ||
| NCT01874470 Details | 2016-10-20 Interventional | 3 | 3 | Antihypertensiv… Diuretics Hypertension Renal Denervati… Resistant Hyper… Standard Medica… | - - | |||
| NCT01227941 Details | 2016-10-19 Interventional | 1 | 6 | Doxorubicin Liposomal doxor… Niraparib Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | - - | |||
| NCT01052311 Details | 2016-10-19 Interventional | 4 | 8 | Niacin Coronary Artery… Coronary Diseas… Dyslipidemias Myocardial Isch… Dyslipidemia | The sponsor decided to withdraw study drug from market - | |||
| NCT00531856 Details | 2016-10-19 Interventional | 2 | 0 | Carbon Monoxide Kidney Transpla… | Clinical Hold pending additional data review and protocol amendment - | |||
| NCT01910155 Details | 2016-10-18 Interventional | 3 | 455 | Ciprofloxacin Dexamethasone Otitis Otitis Externa | FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for
bioequivalence. Small study size resulted in negative culture rates. - | |||
| NCT01144403 2009-011433-27 Details | 2016-10-18 Interventional | 2 | 8 | Cyclophosphamid… Fludarabine Mitoxantrone Rituximab Lymphoma Lymphoma, Large… Lymphoma, Mantl… Diffuse Large B… | - The study was prematurely terminated with 8 participants enrolled, all of them are included into the statistical analyses. | |||
| NCT02454283 Details | 2016-10-17 Interventional | 3 | 41 | Vanoxerine Atrial Fibrilla… Atrial Fibrilla… | Cardiac safety finding - |